CAS NO: | 355151-12-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | Rotigaptide (ZP123) is a novel and specific modulator ofconnexin 43 (Cx43). Rotigaptide prevents the uncoupling of Cx43-mediatedgap junctioncommunication and normalizes cell-to-cell communication during acute metabolic stress. Rotigaptide is a potentantiarrhythmic peptide (AAP)with improved stability and has the potential for the investigation of cardiac arrhythmias-specifically atrial fibrillation[1][2]. | ||||||||||||||||
IC50& Target | IC50: connexin 43 (Cx43)[1] | ||||||||||||||||
体外研究 (In Vitro) | Rotigaptide (100 nM; 24 hours) has a positive effect on cycloheximide-mediated decrease in Cx43 protein levels in cultured neonatal ventricular myocytes[1].Rotigaptide (100 nM; 24 hours) dose not affect INS-1 cell apoptosis itself. And it significantly reduces apoptosis in cytokine-exposed cells ~10% at IL-1b concentrations above 15 pg/ml in rat insulin-producing INS-1 cells[2]. Western Blot Analysis[1]
Apoptosis Analysis[2]
| ||||||||||||||||
体内研究 (In Vivo) | Rotigaptide (intravenous administration; 300 mg/kg; single dose) treatment in mice and rats does not result in toxicity in either species.In escalating dose studies, Rotigaptide (continuous intravenous infusion; 5-14 days) in rats (100 mg/kg) and dogs (10 mg/kg) are well tolerated and produces no compound-related effects or histological toxicological findings[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 617.65 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C28H39N7O9 | ||||||||||||||||
CAS 号 | 355151-12-1 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 200 mg/mL(323.81 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|